Johnson & Johnson in $14.6 Billion Deal to Buy Biotech Intra-Cellular - Barron's

1. Johnson & Johnson agreed to acquire Intra-Cellular Therapies shares. 2. The acquisition aims to enhance JNJ's therapeutic offerings. 3. Financial details of the acquisition were not disclosed. 4. This move positions JNJ in a growing market sector. 5. Investors view acquisitions as strategic growth opportunities.